Current treatment options for craniofacial hyperhidrosis

Detalhes bibliográficos
Autor(a) principal: Wolosker,Nelson
Data de Publicação: 2020
Outros Autores: Faustino,Carolina Brito, Silva,Marcelo Fiorelli Alexandrino da, Campos,José Ribas Milanez de, Kauffman,Paulo
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Jornal Vascular Brasileiro (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-54492020000100413
Resumo: Abstract Hyperhidrosis (HH) is characterized by sweating exceeding the amount necessary to meet the thermal regulation and physiological needs of the body. Approximately 9.41% of individuals with HH have craniofacial hyperhidrosis (FH). The present study aims to review the most current data in the literature regarding craniofacial hyperhidrosis, including pathophysiology, diagnosis and clinical presentation, treatment options (clinical and surgical), and outcomes. VATS (videothoracoscopy sympathectomy) is considered the gold standard for definitive treatment of axillary or palmar hyperhidrosis. Recently, several studies have shown the usefulness of clinical treatment with oxybutynin hydrochloride, leading to clinical improvement of HH in more than 70% of users. Both clinical and surgical treatment of craniofacial hyperhidrosis have good results. However, surgical treatment of FH is associated with more complications. Clinical treatment with oxybutynin hydrochloride yields good results and can be the first therapeutic option. When the patient is not satisfied with this treatment and has good clinical conditions, surgical treatment can be used safely.
id SBACV-1_eb1788fb47b32899da97f16b3db88232
oai_identifier_str oai:scielo:S1677-54492020000100413
network_acronym_str SBACV-1
network_name_str Jornal Vascular Brasileiro (Online)
repository_id_str
spelling Current treatment options for craniofacial hyperhidrosishyperhidrosissympathectomyoxybutyninAbstract Hyperhidrosis (HH) is characterized by sweating exceeding the amount necessary to meet the thermal regulation and physiological needs of the body. Approximately 9.41% of individuals with HH have craniofacial hyperhidrosis (FH). The present study aims to review the most current data in the literature regarding craniofacial hyperhidrosis, including pathophysiology, diagnosis and clinical presentation, treatment options (clinical and surgical), and outcomes. VATS (videothoracoscopy sympathectomy) is considered the gold standard for definitive treatment of axillary or palmar hyperhidrosis. Recently, several studies have shown the usefulness of clinical treatment with oxybutynin hydrochloride, leading to clinical improvement of HH in more than 70% of users. Both clinical and surgical treatment of craniofacial hyperhidrosis have good results. However, surgical treatment of FH is associated with more complications. Clinical treatment with oxybutynin hydrochloride yields good results and can be the first therapeutic option. When the patient is not satisfied with this treatment and has good clinical conditions, surgical treatment can be used safely.Sociedade Brasileira de Angiologia e de Cirurgia Vascular (SBACV)2020-01-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-54492020000100413Jornal Vascular Brasileiro v.19 2020reponame:Jornal Vascular Brasileiro (Online)instname:Sociedade Brasileira de Angiologia e de Cirurgia Vascular (SBACV)instacron:SBACV10.1590/1677-5449.200152info:eu-repo/semantics/openAccessWolosker,NelsonFaustino,Carolina BritoSilva,Marcelo Fiorelli Alexandrino daCampos,José Ribas Milanez deKauffman,Pauloeng2020-11-13T00:00:00Zoai:scielo:S1677-54492020000100413Revistahttp://www.scielo.br/jvbhttps://old.scielo.br/oai/scielo-oai.php||secretaria@sbacv.org.br1677-73011677-5449opendoar:2020-11-13T00:00Jornal Vascular Brasileiro (Online) - Sociedade Brasileira de Angiologia e de Cirurgia Vascular (SBACV)false
dc.title.none.fl_str_mv Current treatment options for craniofacial hyperhidrosis
title Current treatment options for craniofacial hyperhidrosis
spellingShingle Current treatment options for craniofacial hyperhidrosis
Wolosker,Nelson
hyperhidrosis
sympathectomy
oxybutynin
title_short Current treatment options for craniofacial hyperhidrosis
title_full Current treatment options for craniofacial hyperhidrosis
title_fullStr Current treatment options for craniofacial hyperhidrosis
title_full_unstemmed Current treatment options for craniofacial hyperhidrosis
title_sort Current treatment options for craniofacial hyperhidrosis
author Wolosker,Nelson
author_facet Wolosker,Nelson
Faustino,Carolina Brito
Silva,Marcelo Fiorelli Alexandrino da
Campos,José Ribas Milanez de
Kauffman,Paulo
author_role author
author2 Faustino,Carolina Brito
Silva,Marcelo Fiorelli Alexandrino da
Campos,José Ribas Milanez de
Kauffman,Paulo
author2_role author
author
author
author
dc.contributor.author.fl_str_mv Wolosker,Nelson
Faustino,Carolina Brito
Silva,Marcelo Fiorelli Alexandrino da
Campos,José Ribas Milanez de
Kauffman,Paulo
dc.subject.por.fl_str_mv hyperhidrosis
sympathectomy
oxybutynin
topic hyperhidrosis
sympathectomy
oxybutynin
description Abstract Hyperhidrosis (HH) is characterized by sweating exceeding the amount necessary to meet the thermal regulation and physiological needs of the body. Approximately 9.41% of individuals with HH have craniofacial hyperhidrosis (FH). The present study aims to review the most current data in the literature regarding craniofacial hyperhidrosis, including pathophysiology, diagnosis and clinical presentation, treatment options (clinical and surgical), and outcomes. VATS (videothoracoscopy sympathectomy) is considered the gold standard for definitive treatment of axillary or palmar hyperhidrosis. Recently, several studies have shown the usefulness of clinical treatment with oxybutynin hydrochloride, leading to clinical improvement of HH in more than 70% of users. Both clinical and surgical treatment of craniofacial hyperhidrosis have good results. However, surgical treatment of FH is associated with more complications. Clinical treatment with oxybutynin hydrochloride yields good results and can be the first therapeutic option. When the patient is not satisfied with this treatment and has good clinical conditions, surgical treatment can be used safely.
publishDate 2020
dc.date.none.fl_str_mv 2020-01-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-54492020000100413
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-54492020000100413
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/1677-5449.200152
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Sociedade Brasileira de Angiologia e de Cirurgia Vascular (SBACV)
publisher.none.fl_str_mv Sociedade Brasileira de Angiologia e de Cirurgia Vascular (SBACV)
dc.source.none.fl_str_mv Jornal Vascular Brasileiro v.19 2020
reponame:Jornal Vascular Brasileiro (Online)
instname:Sociedade Brasileira de Angiologia e de Cirurgia Vascular (SBACV)
instacron:SBACV
instname_str Sociedade Brasileira de Angiologia e de Cirurgia Vascular (SBACV)
instacron_str SBACV
institution SBACV
reponame_str Jornal Vascular Brasileiro (Online)
collection Jornal Vascular Brasileiro (Online)
repository.name.fl_str_mv Jornal Vascular Brasileiro (Online) - Sociedade Brasileira de Angiologia e de Cirurgia Vascular (SBACV)
repository.mail.fl_str_mv ||secretaria@sbacv.org.br
_version_ 1752126648549900288